CapMedic is a state-of-the-art Class II FDA-cleared solution to remotely monitor and manage Asthma and COPD patients. 

• At the core, it includes a fun, interactive smart inhaler that verbally coaches patients in real-time for regular and correct use. 
• The same device doubles as a smart inhaler to regularly monitor lung function. 
• Without needing to connect to an app, it only takes a few seconds for patients to understand their control and use inhalers correctly but also for clinicians to seamlessly receive rich medication and lung function information. 
• For very young, at-risk, and elderly patients for whom early detection is paramount, the solution includes the first FDA-cleared home usable oscillometry test that requires no forced breathing.

CapMedic is shown to significantly improve inhaler use in published pilots. In a recent pilot, the solution showed 1 week early COPD exacerbation detection capabilities using effort-free oscillometry testing.

Cognita Labs is a California-based respiratory devices innovator with industry first two class II FDA clearances. The company has received prestigious research awards from both NIH and NIH totaling $4M. This means our work has gone through a rigorous review process by both researchers and FDA.

Rimidi’s cardiometabolic platform supports disease management of some of the most prevalent and costly chronic conditions. The platform provides access to the tools required to manage multiple disease states – Diabetes, Cardiovascular Disease/Hypertension, Heart Failure, Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH), and Obesity. The platform consolidates relevant clinical data from the EMR for each disease state with patient-generated health data from connected devices or surveys, and layers clinical decision support that can be mapped against national or practice guidelines. Our cardiometabolic snapshot allows clinicians to quickly assess patient status for each comorbid disease state -- are screenings up to date? Are key metrics well-controlled?

The platform can provide seamless login via SAML-based organization directory sync

• Unparalleled visualizations of inhaler use, lung function, and symptom score tracking.
• Rich reporting
• Customizable alerts
• Automated and manual patient communication via text messaging 

• The first and only live interactive smart inhaler that coaches for inhaler use
• The first and only smart inhaler with sensitive flow sensing that combines smart inhaler and smart spirometer function in one resulting in a single multi-function fun device that patients love
• First reusable and rechargeable device. First, that connects to major MDIs without a change of electronics making it the most environment-friendly product.
• First smart spirometer that requires no app connection for feedback. Results in high patient satisfaction due to the significantly short time commitment per day resulting in high compliance.
• Most comprehensive medication monitoring that includes all MDIs, DPI, and soft mist inhalers.
• Combines most sensitive biomarkers such as spirometry, the technique of inhaler use, and the first FDA-cleared home-use oscillometry test (sensitive lung function assessment without forced breathing)

In the sales process, we often hear “Doesn’t Epic (or other EHR) do that?” Rimidi is not built to replace the EHR, but to enhance it by bringing in additional data sets, providing more efficient workflows, and improving the user experience. Rimidi can install and configure its platform within 3-6 weeks which is significantly faster and more cost effective than onsite EHR teams can build and support enhancements to meet clinical needs. Rimidi’s modern technology stack enables rapid cycle innovation and iteration post-go live.

Rimidi’s cardiometabolic platform is most often compared to other Remote Patient Monitoring solutions, but the platform-approach to RPM allows Rimidi to do so much more. Some key differentiators of the Rimidi platform are: (1) tight integration with leading EHRs via SMART on FHIR, (2) the breadth of the comorbid disease states we cover, (3) our incorporations of patient-reported outcomes and social determinants of health measures and (4) our Clinical Decision Support engine. Rimidi’s CDS cards support almost any insight or intervention a client wants: RPM data alerting and interventions, referral management, lab or medication recommendations, clinical trial identification, and more.